

Blood Test as Standard of Care in Cancer Screening


Todos Medical Ltd. (TOMDF) an Israeli company headquartered in Rehovot, is a cancer in-vitro-diagnostic ("IVD") company engaging in the development of a series of blood tests for the early detection of a variety of cancers. The company's Total Biochemical Infrared Analysis (TBIA) method received CE approval following clinical results with four published peer reviews on its program. The company's lead products consist of screening tests for breast and colon cancers, offering improved current standards of care. The method is low cost with high specificity and sensitivity. It is based on optical/biochemical inspection of blood components. Only 10cc of peripheral blood is needed to run the test. The method is based on optical measurement of the blood sample and computerized analysis. Our method provide a way for early detection of cancer hence saving lives and reducing the payers costs.

Robust Cancer Screening from a Simple Blood Test.

Standard Blood Draw with Todos Kit




Mononuclear Cells & Plasma Separated



FTIR¹ Analysis with Todos Machine Learning Algorithm



Results Reported to Doctor



Note: Fourier Transform Infra-Red (FTIR) spectroscopic analysis of the immune system's response to cancer

The Technology

TBIA: Observing instead of Searching

Todos Medical developed "Total Biochemical Infrared Analysis" (TBIA), a proprietary method for screening of solid tumors using peripheral blood spectroscopy analysis.

The process involves observing the immune system's response/activation to tumor presence rather than looking for the tumor cells themselves or specific biomarkers.

The analysis of the immune system's behavior joined with plasma biochemistry performed by our proprietary algorithm (TodoSpectra), we believe gives a unique, safe, and accurate approach for the important task of cancer screening.

TodoSpectra learns each population (healthy vs. benign vs. cancer) in order meet new markets, new cancers and new demands.

TBIA analyzes the entire biochemical spectral signatures (including proteins, lipids, nucleic acids and carbohydrates) of affected immune cells from peripheral blood, using infrared spectroscopy.

Todos Medical believes that TBIA is **low cost, simple and flexible approach for cancer screening**, represents a major advancement over competitive technologies that focus on identifying specific biomarker proteins which induce high false positive results.

Our IP:

Three patents granted and more pending protecting our unique TBIA technology.

Our Products:

TM-B1 and TM-B2 for Breast Cancer – with approximately 90% accuracy, these test intend to target unmet need for woman with dense breast tissue, young woman below the age of 50, and to reduce unnecessary biopsies following positive mammography.

TM-C1 for Colorectal Cancer - targeting the detection of colorectal cancers at an early stage.

Our Publications:

Four high impact peer reviewed publications describing our achievements in detection of breast cancer, colorectal cancer as well as other types of cancers.

Accessibility of Blood Tests Yields Large, Addressable Market Opportunities

- Total available market (TAM) estimated at more than 600M tests a year in 2021
- Additional indications planned to follow, with increasing penetration and adoption



Multi-pronged Development Plan

Europe & Israel:

- CE Mark approved for European sales
- For commercialization in Europe and other CE regulated countries

Singapore + Asia:

- Breast cancer clinical trials in Singapore; colon cancer to follow

Plans for the US:

- Planning and Pre-IDE meetings with the FDA
- IDE filing and initiation of regulatory process
- Large scale FDA clinical trials

Experienced Leadership

Herman Weiss, MD, MBA, FACOG - CEO

Dr. Weiss has served as Chairman of Todos Medical and has recently assumed the position of CEO. Dr. Weiss has held senior management positions for Juniper Pharmaceuticals and Teva Pharmaceuticals.

Rami Zigdon, CBO & Co-Founder (EEng., BSC, MBA)

Seasoned executive in high-tech companies with over 25 years experience in R&D, Sales & Marketing, and Management. Prior positions with Hitachi Semiconductors, Renesas Technologies, Atmel, Scitex (Kodak).

Dr. Udi Zelig, CTO & Co-Founder

Over 10 years in biomedical engineering; Academic at Ben Gurion University with numerous medical and biophysics publications.

Joseph Wee, Managing Director - Singapore

Over 45 years as a Productivity and Business Management Consultant to SMEs, MNCs, Government Linked Companies and Government Agencies.

This presentation contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, those statements regarding the Company’s lead product candidates and their effectiveness in improving the current standards of care, the Company’s future marketing and development plans, the company’s belief that its products represent a major advancement over competitive technologies and the Company’s projections for the total available market for its products. These forward-looking statements and their implications are based on the current expectations of the management of the Company only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained in the Company’s filings made with the U.S. Securities and Exchange Commission.